Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients

被引：15

作者：

Tom, Sean K. ^{[1
]}

Yau, Yvonne C. W. ^{[2
]}

Beaudoin, Trevor ^{[1
]}

LiPuma, John J. ^{[3
]}

Waters, Valerie ^{[1
]}

机构：

[1] Univ Toronto, Hosp Sick Children, Dept Pediat, Div Infect Dis, Toronto, ON M5G 1X8, Canada

[2] Univ Toronto, Hosp Sick Children, Dept Pediat Lab Med, Div Microbiol, Toronto, ON M5G 1X8, Canada

[3] Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2016年 / 60卷 / 01期

关键词：

SUSCEPTIBILITY; XYLOSOXIDANS;

D O I：

10.1128/AAC.02240-15

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

MICs and biofilm inhibitory concentrations (BICs) were measured for 68 cystic fibrosis (CF) Achromobacter isolates for amikacin, aztreonam, colistin, levofloxacin, and tobramycin. With the exception of colistin and levofloxacin, the remaining antibiotics had MIC(90)s, BICs at which 50% of the isolates were susceptible (BIC(50)s), and BICs at which 90% of the isolates were susceptible (BIC(90)s) equal to or above the highest concentrations tested. In a biofilm model, tobramycin was able to significantly increase killing of bacterial cells compared to controls, for intermediate-resistant strains only, at concentrations of 1,000 and 2,000 mu g/ml.

引用

页码：650 / 652

页数：3

共 16 条

[1] [Anonymous], M100S22 CLSI
[2] Innate Aminoglycoside Resistance of Achromobacter xylosoxidans Is Due to AxyXY-OprZ, an RND-Type Multidrug Efflux Pump
Bador, Julien
Amoureux, Lucie
Blanc, Emmanuel
Neuwirth, Catherine
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (01) : 603 - 605
[3] Evaluation of colistin susceptibility in multidrug-resistant clinical isolates from cystic fibrosis, France
Biswas, S.
Dubus, J. -C.
Reynaud-Gaubert, M.
Stremler, N.
Rolain, J. -M.
[J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2013, 32 (11) : 1461 - 1464
[4] Chmiel James F, 2014, Ann Am Thorac Soc, V11, P1120, DOI 10.1513/AnnalsATS.201402-050AS
[5] Achromobacter xylosoxidans in cystic fibrosis:: Prevalence and clinical relevance
De Baets, Frans
Schelstraete, Petra
Van Daele, Sabine
Haerynck, Filomeen
Vaneechoutte, Mario
[J]. JOURNAL OF CYSTIC FIBROSIS, 2007, 6 (01) : 75 - 78
[6] Changes in Cystic Fibrosis Sputum Microbiology in the United States Between 1995 and 2008
Emerson, Julia
McNamara, Sharon
Buccat, Anne Marie
Worrell, Kelly
Burns, Jane L.
[J]. PEDIATRIC PULMONOLOGY, 2010, 45 (04) : 363 - 370
[7] Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients;: a retrospective case control study
Hansen, Christine Ronne
Pressler, Tacjana
Hoiby, Niels
Gormsen, Magdalena
[J]. JOURNAL OF CYSTIC FIBROSIS, 2006, 5 (04) : 245 - 251
[8] Complete Genome Sequence of the Cystic Fibrosis Pathogen Achromobacter xylosoxidans NH44784-1996 Complies with Important Pathogenic Phenotypes
Jakobsen, Tim Holm
Hansen, Martin Asser
Jensen, Peter Ostrup
Hansen, Lars
Riber, Leise
Cockburn, April
Kolpen, Mette
Hansen, Christine Ronne
Ridderberg, Winnie
Eickhardt, Steffen
Hansen, Marlene
Kerpedjiev, Peter
Alhede, Morten
Qvortrup, Klaus
Burmolle, Mette
Moser, Claus
Kuhl, Michael
Ciofu, Oana
Givskov, Michael
Sorensen, Soren J.
Hoiby, Niels
Bjarnsholt, Thomas
[J]. PLOS ONE, 2013, 8 (07):
[9] Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients
Lambiase, A.
Catania, M. R.
del Pezzo, M.
Rossano, F.
Terlizzi, V.
Sepe, A.
Raia, V.
[J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2011, 30 (08) : 973 - 980
[10] SUSCEPTIBILITY OF ALCALIGENES-DENITRIFICANS SUBSPECIES XYLOS-OXYDANS TO BETA-LACTAM ANTIBIOTICS
MENSAH, K
PHILIPPON, A
RICHARD, C
NEVOT, P
[J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1990, 9 (06) : 405 - 409

← 1 2 →